Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Hemogenyx Pharmaceuticals Plc | LSE:HEMO | London | Ordinary Share | GB00BYX3WZ24 | ORD GBP0.01 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | |
|---|---|---|---|---|---|
| -0.083 | -5.78% | 1.352 | 1.352 | 1.598 |
| High Price | Low Price | Open Price | Shares Traded | Last Trade |
|---|---|---|---|---|
| 1.352 | 1.352 | 1.352 | 163,232 | 08:30:09 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Finance Services | 0 | -6.69M | -0.0050 | -2.86 | 19.26M |
| Date | Time | Source | Headline |
|---|---|---|---|
| 11/11/2024 | 07:00 | UK RNS | Hemogenyx Pharmaceuticals PLC Institutional Investment |
| 30/10/2024 | 11:09 | ALNC |  IN BRIEF: Hemogenyx to launch myeloid leukemia treatment phase 1 trial |
| 30/10/2024 | 07:00 | UK RNS | Hemogenyx Pharmaceuticals PLC Schedule for Phase I Clinical Trial Opening |
| 02/10/2024 | 10:19 | UK RNS | Hemogenyx Pharmaceuticals PLC Strategic Investment from Prevail Partners,.. |
| 27/9/2024 | 17:25 | ALNC | Hemogenyx Pharmaceuticals loss narrows amid reduced expenses |
| 27/9/2024 | 14:55 | ALNC | EARNINGS: Clean Power Hydrogen loss widens; Invinity loss narrows |
| 27/9/2024 | 06:00 | UK RNS | Hemogenyx Pharmaceuticals PLC Half-year Report |
| 09/9/2024 | 21:03 | ALNC | TRADING UPDATES: Light Science Technologies wins two new contracts |
| 09/9/2024 | 06:00 | UK RNS | Hemogenyx Pharmaceuticals PLC FLT3 Assay Ready for Phase I Trials at MD.. |
| 02/9/2024 | 06:00 | UK RNS | Hemogenyx Pharmaceuticals PLC CDX Development Update |
1 Year Hemogenyx Pharmaceuticals Chart |
Intraday Hemogenyx Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
